Cognito Therapeutics, Inc.

Cognito Therapeutics, Inc. company information, Employees & Contact Information

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Company Details

Employees
52
Founded
-
Address
Cambridge, Ma 02138, Us
Phone
857-201-5088
Email
in****@****otx.com
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
Keywords
Engineer jobs.
HQ
Cambridge, MA
Looking for a particular Cognito Therapeutics, Inc. employee's phone or email?

Cognito Therapeutics, Inc. Questions

News

Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease - Business Wire

Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease Business Wire

Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer - citybiz

Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer citybiz

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025 - Yahoo Finance

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025 Yahoo Finance

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile - Business Wire

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile Business Wire

Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer - citybiz

Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer citybiz

Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease - Business Wire

Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease Business Wire

Cognito Therapeutics Appoints Ralph Kern, M.D., as CMO and Kim Kwan as CTO - citybiz

Cognito Therapeutics Appoints Ralph Kern, M.D., as CMO and Kim Kwan as CTO citybiz

Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board - citybiz

Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board citybiz

Top Cognito Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant